Avoiding Double-Counting in Pharmacoeconomic Studies Magnus Johannesson Leading Article 25 November 2012 Pages: 385 - 388
The Effect of Pharmacoeconomics on Company Research and Development Decisions Henry Grabowski Leading Article 25 November 2012 Pages: 389 - 397
The Economic Aspects of Drug Delivery in Asthma R. John MassieCraig M. Mellis Review Article 25 November 2012 Pages: 398 - 407
Cost Considerations in the Pharmacological Prevention and Treatment of Stroke Andrei V. AlexandrovLiliana T. SmurawskaPaul Oh Review Article 25 November 2012 Pages: 408 - 418
Constraints on Antidepressant Prescribing and Principles of Cost-Effective Antidepressant Use John A. HenryCarol A. Rivas Review Article 25 November 2012 Pages: 419 - 443
Drug Treatments for Maintaining Remission in Crohn’s Disease Giacomo TralloriAndrea Messori Original Research Article 25 November 2012 Pages: 444 - 453
Autologous Peripheral Blood Progenitor-Cell Transplantation versus Autologous Bone Marrow Transplantation for Adults and Children with Non-Leukaemic Malignant Disease Anne-Gaëlle Le CorrollerCatherine FaucherJean-Paul Moatti Original Research Article 25 November 2012 Pages: 454 - 463
Bootstrap Analyses of Cost Effectiveness in Antidepressant Pharmacotherapy Robert L. ObenchainCatherine A. MelfiDon P. Buesching Original Research Article 25 November 2012 Pages: 464 - 472
Sumatriptan Allan J. CoukellHarriet M. Lamb Adis Pharmacoeconomic Drug Evaluation 25 November 2012 Pages: 473 - 490
Interferon-α in Hepatitis C: The Authors’ Reply Andrew BriggsAlan Shiell Correspondence 25 November 2012 Pages: 491 - 492
Cost Utility in Second-Line Metastatic Breast Cancer Gilles BerdeauxPatrick Hurteloup Correspondence 25 November 2012 Pages: 492 - 495
Cost Utility in Second-Line Metastatic Breast Cancer: The Authors’ Reply Robert LaunoisJeanne Reboul-MartyJacques Bonneterre Correspondence 25 November 2012 Pages: 495 - 497